Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Growth Stock Watch: NxStage Medical, Inc. (NASDAQ:NXTM) - Enterprise Leader |
 |
 |
|
NxStage Medical, Inc. (NASDAQ:NXTM) has been given a positive Growth Style Score by Zacks Research. The Growth score analyzes the growth prospects for a company in addition to analyzing company financials. The score takes into account various measures of the Income Statement, Cash Flow Statement and Balance Sheet to achieve a ranking of A-F, where A indicates that the stock has the best growth characteristics likely to outperform the market. Analysts tracked by Zacks have given NxStage Medical, Inc. a mean long term growth estimate of 18.33. This number is based on sales and earnings over the next 3-5 years, calculated on a consensus basis. On a shorter term basis, analysts have a projected price target of $21 on the equity. This is a one-year consensus target based on 4 sell-side analysts providing estimates. The firm with the most bullish sentiment sees the stock reaching $24 while the most conservative has the target set at $15. Sell-side firms use a variety of different terms such a Buy, Sell and Hold to rate their outlook on stocks. Using a simplified scale where Strong Buy equals 1 and Strong Sell equals 5, the consensus simplified rating for NxStage Medical, Inc. is 2. NxStage Medical, Inc. (NASDAQ:NXTM) is next slated to report quarterly results on 2015-08-06 where the Street is anticipating earnings per share of $-0.1. Most recently the firm reported earnings of $0 for the period ending on 2015-03-31. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market. |
